[Late-Onset Dyskinesia Occurring During Antipsychotic Treatment for Schizophrenia: Management of Tardive Dyskinesia Based on the Latest Knowledge]

Brain Nerve. 2022 May;74(5):571-574. doi: 10.11477/mf.1416202082.
[Article in Japanese]

Abstract

Tardive dyskinesia is a drug-induced involuntary movement related to long-term use of dopamine receptor-blocking agents. If there is no improvement upon discontinuation or change in the causative drug, treatment needs to be initiated. The most effective drug is the vesicular monoamine transporter 2 selective inhibitor. Other drugs, such as clonazepam, amantadine, yokukansan, and Ginkgo biloba extract, may be effective in some patients. Botulinum toxin treatment and deep brain stimulation are potential treatment options for patients with tardive dyskinesia that is refractory to the aforementioned agents. Optimal treatment should be selected while monitoring for mental illnesses.

MeSH terms

  • Antipsychotic Agents* / adverse effects
  • Dyskinesias*
  • Humans
  • Schizophrenia* / drug therapy
  • Tardive Dyskinesia* / chemically induced
  • Tardive Dyskinesia* / drug therapy
  • Tetrabenazine / adverse effects

Substances

  • Antipsychotic Agents
  • Tetrabenazine